Phase I/II Study of CAR.70- Engineered IL15-transduced Cord Blood-derived NK Cells in Conjunction With Lymphodepleting Chemotherapy for the Management of Relapse/Refractory Hematological Malignances
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
Xencor, Inc.
Children's Oncology Group
M.D. Anderson Cancer Center
Loma Linda University
Seattle Children's Hospital
Indiana University
Assistance Publique - Hôpitaux de Paris
St. Jude Children's Research Hospital
Nationwide Children's Hospital
Sun Yat-sen University
Heinrich-Heine University, Duesseldorf
Baylor College of Medicine
National Cancer Institute, Slovakia
N.N. Petrov National Medical Research Center of Oncology
Turning Point Therapeutics, Inc.
Gustave Roussy, Cancer Campus, Grand Paris
Indiana University
Bambino Gesù Hospital and Research Institute
Jules Bordet Institute